title: Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study.
abstract: Thirteen children with difficult systemic onset juvenile rheumatoid arthritis were treated with thalidomide. At 6 months, 11 of the 13 were able to reduce their use of prednisone ( P < .002), with a concurrent improvement in erythrocyte sedimentation rate ( P < .0001) and an increase in hemoglobin level ( P < 0.005). Juvenile rheumatoid arthritis improvement scores >/=50% were obtained by 10 of the 13 children.
authors.affiliation: Division of Pediatric Rheumatology, Hospital for Special Surgery, and the Department of Pediatrics, Sanford Weill Medical College of Cornell University, New York, New York, USA.
authors.forename: Thomas J A
authors.initials: TJ
authors.lastname: Lehman
authors.forename: Sharon J
authors.initials: SJ
authors.lastname: Schechter
authors.forename: Robert P
authors.initials: RP
authors.lastname: Sundel
authors.forename: Sheila K
authors.initials: SK
authors.lastname: Oliveira
authors.forename: Anna
authors.initials: A
authors.lastname: Huttenlocher
authors.forename: Karen B
authors.initials: KB
authors.lastname: Onel
mesh_terms: D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001799:Blood Sedimentation / Q000187:drug effects; D002648:Child; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide